Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 003 - Coagulant Therapeutics

Next Previous
X
Search
Drug Profile

CT 003 - Coagulant Therapeutics

Alternative Names: CT-003 - Coagulant Therapeutics

Latest Information Update: 03 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Haemorrhage

Most Recent Events

  • 18 Jul 2022 CT 003 - Coagulant Therapeutics is available for licensing as of 11 Jul 2022. https://www.coagulanttherapeutics.com/partner
  • 11 Jul 2022 Early research in Haemorrhage in South Korea (Parenteral) before July 2022 (Coagulant Therapeutics pipeline, July 2022)
  • 11 Jul 2022 Coagulant Therapeutics plans a phase I trial in Haemorrhage in first half of 2025 (Coagulant Therapeutics pipeline, June 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top